Prostatyba, MB - company info and details

Company age: 4 y. 2 mo.

Update

Company overview

Company name Prostatyba, MB
Company code 306136857
VAT code LT100016178316
Registered address Vilnius, V. Nagevičiaus g. 3, LT-08237
Registration date 2022-08-29 Company age: 4 y. 2 mo.
Phone Phone
Email Email
Website None
Company manager For registered members only Log in
Revenue (2025) 84,964 € -15% History
Profit (2025) 6,020 € -39% History
Number of employees 0 History
Managed vehicles 0
Current SODRA debt No debt Read more
Days of debt to SODRA per year 65 days
Current VMI debt No debt Read more
Financial statements All submitted
Legal form Small partnership
NACE activity New construction
Ownership form Private without foreign capital

Description

This description was generated by artificial intelligence.
Prostatyba, MB (company code 306136857) is an operational private small partnership registered on 29 August 2022. It belongs to the sector of national private non-financial companies and is privately owned, with more than 50% of the authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. The governance structure is CEO only, and the company is classified as micro-sized. Its main activity is EVRK F.41.00.10, New construction. The company is based in Vilnius, at V. Nageviciaus g. 3, Vilniaus m. sav., Vilniaus apskr.

Financially, Prostatyba generated revenue of €85.0K in 2025, down from €100.2K in 2024, while net profit was €6.0K after €9.8K in the previous year. The profit margin was 7.1% in 2025. Compared with 2023, when revenue was €92.3K and the company was close to break-even, the business returned to profitability in 2024 and remained profitable in 2025, although at a lower revenue level. At year-end 2025, equity stood at €15.8K, liabilities at €11.2K, and total assets at €3.8K. The company averaged 1 employee in 2024 and 2025; in 2023 it averaged 3 employees, with an average monthly wage of €632.73.

Download a detailed company report

Make confident decisions with all the information about Prostatyba, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report